---

Highlights of November 2018

1. Cipla‘s InvaGen Pharma to acquire US-based  Avenue Therapeutics (Fortress Bio company) for up to US$ 215 Million.
2. Strides entered into a partnership with Australia’s SUDA Pharmaceuticals for its drug SUD-001H used to treat migraine.
3. Aurobindo Pharma USA Inc has signed a pact to acquire an under-development product and certain related assets from Australian Advent Pharmaceuticals Pty Ltd for US$ 12.5 Million.
4. Sun Pharma to acquire Japan’s Pola Pharma for US$ 1 Million.
5. WuXi NextCODE acquires GMI as part of US$ 400 Million genomics research push in Ireland.
6. Synteract snaps up pediatric CRO Kinder Pharm for undisclosed price.
7. Roivant takes aim at resistant infections with US$ 667.5 Million Intron deal.
8. Merck KGaA, Palantir form new JV aimed at breaking down cancer data silos.
9. LEO Pharma inks US$ 760 Million rare skin disease R&D deal with PellePharm.
10. Cambrex adds Avista Pharma to the fold in US$ 250 Million deal.
11. Implant maker ChoiceSpine acquired by Altus Capital Partners.
12. Johnson & Johnson Vision inked a US$ 26.35 Million collaboration with the Singapore Eye Research institute, focused on treating nearsightedness.
13. AbbVie inks licensing deal to boost its pan-genotypic hepatitis C drug Mavyret's access in nearly 100 countries.
14. AstraZeneca offloads RSV drug to Sobi for US$ 1.5 Billion.
15. Embark and Novo Nordisk enter collaboration to discover novel therapeutics for obesity and metabolic disease.
16. Illumina buys Pacific Biosciences for US$ 1.2 Billion to shore up DNA sequencing dominance.

Updates at Aagami: 

1. Aagami CEO and Vice President along with US based client to go on CXO Level roadshow for strategic partnership with Indian Companies.
2. Aagami CEO along with another client to go on CEO level roadshow for strategic partnership in non-clinical/preclinical drug development strategies.
3. Aagami to attend Biotech Showcase in San Francisco 7 - 9 January 2019. Available to meet other companies on Jan 10 and 11 too.